MYH16上调与肺腺癌的攻击性和免疫透有关
Libin Zhang1, Jun Liu2, Han Wang2
1Thoracic Surgery Department, Yan'an Hospital Affiliated to Kunming Medical University, Kunming City, Yunnan Province, China.
Journal of biochemical and molecular toxicology
|August 17, 2023
概括
髓重链16 (MYH16) 在肺腺癌 (LUAD) 中被上调,与更差的存活率和增加的免疫细胞透相关. 这一发现凸显了MYH16作为LUAD患者潜在的预后指标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 已知氨酸重链16 (MYH16) 在细胞周期进展中的作用,但其在肺腺癌 (LUAD) 的临床意义尚不清楚.
- 关于MYH16在泛癌情境中的上调调节的数据有限,需要对其在LUAD中的特定作用进行调查.
研究的目的:
- 调查MYH16在肺腺癌 (LUAD) 上调的临床相关性和预后价值.
- 探索MYH16表达,临床因素,瘤免疫透和LUAD生存结果之间的关联.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据对LUAD中的MYH16表达模式进行生物信息学分析.
- 用Kaplan-Meier绘图器进行生存分析和TIMER工具进行瘤免疫透评估.
- 进行基因组丰富分析 (GSEA) 来识别MYH16相关途径,并构建了用于预后预测的诺米图.
主要成果:
- 发现MYH16在LUAD中异常上调,与瘤阶段相关,整体存活率更差,特别是在女性中.
- MYH16过度表达与瘤免疫细胞透率的增加有关,并被确定为LUAD的独立预后指标.
- BMP6 缺陷与 MYH16 的上调有关,GSEA 建议 MYH16 通过 RNA 信号来调解半变异和基因沉默.
结论:
- 在LUAD中MYH16上调与临床风险因素,晚期癌症,增强的免疫透和较差的生存率有关.
- MYH16作为肺腺癌的潜在独立预后生物标志物.
- 对MYH16在变和RNA信号传递中的作用的进一步研究可能会揭示LUAD的治疗策略.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K


